Summary
Background A substantial proportion of solid tumors carry the BRAF V600E mutation, which causes activation of the MEK/MAPK pathway and is a poor prognostic indicator. Patients with locally advanced human cancers are often treated with external beam radiation therapy. Given the association of Raf overactivation with radioresistance, we hypothesized that, in BRAF V600E-mutated carcinomas, there would be combinatorial activity between radiation and PLX4720, a specific BRAF V600E-inhibitor. Methods Two BRAF V600E-mutated cancer cell lines and one BRAF-V600E wildtype (WT) cancer cell line were obtained. We performed cell viability assays and clonogenic assays using combinations of radiation and PLX4720. We assessed MEK and MAPK phosphorylation at different PLX4720 concentrations with western blotting, and cell cycle progression was evaluated by flow cytometry. Results Our results show combinatorial, additive activity between radiation and PLX4720 in BRAF V600E-mutated cell lines, but not in the BRAF WT line. In BRAF V600E-mutated cells, there was a PLX4720 concentration-dependent decrease in MEK and MAPK phosphorylation. In cells with BRAF V600E mutations, PLX4720 caused cell cycle arrest at G1, and, when combined with radiation, caused a combined G1 and G2 cell cycle arrest; this pattern of cell cycle effects was not seen in the BRAF WT cell line. Conclusions These data suggest additive, combinatorial activity between radiation and PLX4720 in cancers carrying BRAF V600E mutations. Our data has potential for translation into the multimodality treatment of BRAF V600E-mutated cancers.
Similar content being viewed by others
References
McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Montalto G, Cervello M, Nicoletti F, Fagone P, Malaponte G, Mazzarino MC, Candido S, Libra M, Basecke J, Mijatovic S, Maksimovic-Ivanic D, Milella M, Tafuri A, Cocco L, Evangelisti C, Chiarini F, Martelli AM (2012) Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades. Oncotarget (9):954–87
Gokhale PC, McRae D, Monia BP, Bagg A, Rahman A, Dritschilo A, Kasid U (1999) Antisense raf oligodeoxyribonucleotide is a radiosensitizer in vivo. Antisense Nucleic Acid Drug Dev 9(2):191–201
Smallridge RC, Marlow LA, Copland JA (2009) Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer 16(1):17–44. doi:https://doi.org/10.1677/ERC-08-0154
Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, Janakiraman M, Solit D, Knauf JA, Tuttle RM, Ghossein RA, Fagin JA (2009) Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 69(11):4885–4893. doi:https://doi.org/10.1158/0008-5472.CAN-09-0727
Schiffman JD, Hodgson JG, VandenBerg SR, Flaherty P, Polley MY, Yu M, Fisher PG, Rowitch DH, Ford JM, Berger MS, Ji H, Gutmann DH, James CD (2010) Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res 70(2):512–519. doi:https://doi.org/10.1158/0008-5472.CAN-09-1851
Xing M (2010) Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol Cell Endocrinol 321(1):86–93. doi:https://doi.org/10.1016/j.mce.2009.10.012
Nucera C, Lawler J, Hodin R, Parangi S (2010) The BRAFV600E mutation: what is it really orchestrating in thyroid cancer? Oncotarget 1(8):751–756
Horbinski C, Nikiforova MN, Hagenkord JM, Hamilton RL, Pollack IF (2012) Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas. Neuro Oncol 14(6):777–789. doi:https://doi.org/10.1093/neuonc/nos077
Safaee Ardekani G, Jafarnejad SM, Tan L, Saeedi A, Li G (2012) The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS One 7(10):e47054. doi:https://doi.org/10.1371/journal.pone.0047054
Kasid U, Dritschilo A (2003) RAF antisense oligonucleotide as a tumor radiosensitizer. Oncogene 22(37):5876–5884. doi:https://doi.org/10.1038/sj.onc.1206700
Nucera C, Goldfarb M, Hodin R, Parangi S (2009) Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E). Biochim Biophys Acta 1795(2):152–161. doi:https://doi.org/10.1016/j.bbcan.2009.01.003
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O’Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507–2516. doi:https://doi.org/10.1056/NEJMoa1103782
Sala E, Mologni L, Truffa S, Gaetano C, Bollag GE, Gambacorti-Passerini C (2008) BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol Cancer Res 6(5):751–759. doi:https://doi.org/10.1158/1541-7786.MCR-07-2001
Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C (2006) Clonogenic assay of cells in vitro. Nat Protoc 1(5):2315–2319. doi:https://doi.org/10.1038/nprot.2006.339
Xing J, Liu R, Xing M, Trink B (2011) The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204). Biochem Biophys Res Commun 404(4):958–962. doi:https://doi.org/10.1016/j.bbrc.2010.12.088
Salerno P, De Falco V, Tamburrino A, Nappi TC, Vecchio G, Schweppe RE, Bollag G, Santoro M, Salvatore G (2010) Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. J Clin Endocrinol Metab 95(1):450–455. doi:https://doi.org/10.1210/jc.2009-0373
Sambade MJ, Peters EC, Thomas NE, Kaufmann WK, Kimple RJ, Shields JM (2011) Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032. Radiother Oncol J Eur Soc Ther Radiol Oncol 98(3):394–399. doi:https://doi.org/10.1016/j.radonc.2010.12.017
Dasgupta T, Yang X, Hashizume R, Olow A, Kolkowitz I, Weiss W, Mueller S, Nicolaides T, James CD, Haas-Kogan DA (2012) Survival advantage with radiation combined with a selective BRAF V600E inhibitor in an orthotopic, intracranial model of BRAF V600E-mutated high-grade gliomas. Int J Radiat Oncol Biol Phys 84(3):S125
Dasgupta T, Yom SS, Yang X, Sottero T, Nicolaides TP, James CD, Haas-Kogan DA (2010) B-Raf inhibitor PLX4720 enhances the activity of temozolamide and radiation in a human glioblastoma cell line. Int J Radiat Oncol Biol Phys 78(3):S169, abstract number 2992
Nicolaides TP, Li H, Solomon DA, Hariono S, Hashizume R, Barkovich K, Baker SJ, Paugh BS, Jones C, Forshew T, Hindley GF, Hodgson JG, Kim JS, Rowitch DH, Weiss WA, Waldman TA, James CD (2011) Targeted therapy for BRAFV600E malignant astrocytoma. Clin Cancer Res Off J Am Assoc Cancer Res 17(24):7595–7604. doi:https://doi.org/10.1158/1078-0432.CCR-11-1456
Mueller S, Yang X, Sottero TL, Gragg A, Prasad G, Polley MY, Weiss WA, Matthay KK, Davidoff AM, DuBois SG, Haas-Kogan DA (2011) Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms. Cancer Lett 306(2):223–229. doi:https://doi.org/10.1016/j.canlet.2011.03.010
Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland JA, Smallridge RC, Haugen BR (2008) Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 93(11):4331–4341. doi:https://doi.org/10.1210/jc.2008-1102
Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr, Kaempgen E, Martin-Algarra S, Karaszewska B, Mauch C, Chiarion-Sileni V, Martin AM, Swann S, Haney P, Mirakhur B, Guckert ME, Goodman V, Chapman PB (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380(9839):358–365. doi:https://doi.org/10.1016/S0140-6736(12)60868-X
Flaherty KT (2012) Dividing and conquering: controlling advanced melanoma by targeting oncogene-defined subsets. Clin Exp Metastasis 29(7):841–846. doi:https://doi.org/10.1007/s10585-012-9488-y
Acknowledgments
We thank Plexxikon, Inc. for providing PLX4720, and Dr. Brian L. West for this thoughtful advice and assistance during this study.
Author disclosures and conflict of interest
None. The authors report no conflict of interest.
Ethical standards
The submitted manuscript complies with the current laws of the country, the United States of America, in which the experiments and analysis were performed.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dasgupta, T., Haas-Kogan, D.A., Yang, X. et al. Genotype-dependent cooperation of ionizing radiation with BRAF inhibition in BRAF V600E-mutated carcinomas. Invest New Drugs 31, 1136–1141 (2013). https://doi.org/10.1007/s10637-013-9928-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-013-9928-9